MoonLake Immunotherapeutics - Class A MLTX

NAS: MLTX | ISIN: KY61559X1045   2/04/2026
17,36 USD (+5,08%)
(+5,08%)   2/04/2026

28 maart 2026 · MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting · Persbericht

22 februari 2026 · MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results · Persbericht

2 februari 2026 · MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day · Persbericht

8 januari 2026 · MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day · Persbericht

12 december 2025 · MLTX DEADLINE: Faruqi & Faruqi Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX · Persbericht

12 december 2025 · MoonLake Immunotherapeutics Class Action: Levi & Korsinsky Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX · Persbericht

11 december 2025 · DEADLINE NEXT WEEK: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Contact the Firm Before December 15, 2025 · Persbericht

9 december 2025 · Investors in MoonLake Immunotherapeutics Should Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX · Persbericht

5 december 2025 · Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Seeking Recovery for Investors - Contact Levi & Korsinsky · Persbericht

5 december 2025 · SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics · Persbericht

5 december 2025 · MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman · Persbericht

3 december 2025 · MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman · Persbericht

2 december 2025 · MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX · Persbericht

2 december 2025 · MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority · Persbericht

1 december 2025 · MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

1 december 2025 · MoonLake Immunotherapeutics (NASDAQ: MLTX) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit · Persbericht

30 november 2025 · Faruqi & Faruqi Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX · Persbericht

28 november 2025 · MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman · Persbericht

26 november 2025 · MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman · Persbericht

25 november 2025 · MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman · Persbericht

Mijn selecties